We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
74 hedge funds and large institutions have $98.5M invested in Lineage Cell Therapeutics in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
3.4% more ownership
Funds ownership: 46.25% → 49.66% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 80 → 74 (-6)
13% less capital invested
Capital invested by funds: $113M → $98.5M (-$14.2M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
78% less call options, than puts
Call options by funds: $113K | Put options by funds: $508K
Holders
74
Holders Change
-6
Holders Change %
-7.5%
% of All Funds
2.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
18
Reduced
24
Closed
13
Calls
$113K
Puts
$508K
Net Calls
-$395K
Net Calls Change
-$2.97M
Top Buyers
| 1 |
BC
Broadwood Capital
New York
|
+$7.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$646K |
| 3 |
Jane Street
New York
|
+$402K |
| 4 |
V
Veritable
Wilmington,
Delaware
|
+$241K |
| 5 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
+$144K |
